Azithromycin use for trachoma control

Lessons learned from Tanzania

Sheila K West, Harran Mkocha

Research output: Contribution to journalArticle

Abstract

Trachoma, the leading infectious cause of blindness, is a chronic conjunctivitis caused by repeated reinfections with Chlamydia trachomatis. Trachoma is a disease of entire communities, with the reservoir of infection residing in children, especially preschool children. The World Health Assembly has targeted the year 2020 for the elimination of blinding trachoma as a public health problem, and mass treatment with antibiotics is part of the multifaceted SAFE strategy recommended for country programs. Tanzania was one of the first countries to be the recipient of azithromycin for use in mass distribution programs and has been the site of a continuous research effort on trachoma control in the Kongwa district, the Kongwa Trachoma Project, since 1986. The authors discuss some events leading up to the use of azithromycin for trachoma, our experiences and lessons learned with use of azithromycin, intervention goals, achieving high coverage and the challenges to achieving elimination by 2020.

Original languageEnglish (US)
Pages (from-to)245-253
Number of pages9
JournalExpert Review of Ophthalmology
Volume8
Issue number3
DOIs
StatePublished - Jun 2013

Fingerprint

Trachoma
Azithromycin
Tanzania
Public health
Antibiotics
Medical problems
Health
Conjunctivitis
Chlamydia trachomatis
Preschool Children
Blindness
Public Health
Anti-Bacterial Agents
Infection
Research

Keywords

  • azithromycin
  • ocular Chlamydia trachomatis infection
  • population study
  • Tanzania
  • trachoma

ASJC Scopus subject areas

  • Ophthalmology
  • Biomedical Engineering
  • Optometry

Cite this

Azithromycin use for trachoma control : Lessons learned from Tanzania. / West, Sheila K; Mkocha, Harran.

In: Expert Review of Ophthalmology, Vol. 8, No. 3, 06.2013, p. 245-253.

Research output: Contribution to journalArticle

@article{6844480a28584fd7a75f7b71fadbcf66,
title = "Azithromycin use for trachoma control: Lessons learned from Tanzania",
abstract = "Trachoma, the leading infectious cause of blindness, is a chronic conjunctivitis caused by repeated reinfections with Chlamydia trachomatis. Trachoma is a disease of entire communities, with the reservoir of infection residing in children, especially preschool children. The World Health Assembly has targeted the year 2020 for the elimination of blinding trachoma as a public health problem, and mass treatment with antibiotics is part of the multifaceted SAFE strategy recommended for country programs. Tanzania was one of the first countries to be the recipient of azithromycin for use in mass distribution programs and has been the site of a continuous research effort on trachoma control in the Kongwa district, the Kongwa Trachoma Project, since 1986. The authors discuss some events leading up to the use of azithromycin for trachoma, our experiences and lessons learned with use of azithromycin, intervention goals, achieving high coverage and the challenges to achieving elimination by 2020.",
keywords = "azithromycin, ocular Chlamydia trachomatis infection, population study, Tanzania, trachoma",
author = "West, {Sheila K} and Harran Mkocha",
year = "2013",
month = "6",
doi = "10.1586/eop.13.18",
language = "English (US)",
volume = "8",
pages = "245--253",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Azithromycin use for trachoma control

T2 - Lessons learned from Tanzania

AU - West, Sheila K

AU - Mkocha, Harran

PY - 2013/6

Y1 - 2013/6

N2 - Trachoma, the leading infectious cause of blindness, is a chronic conjunctivitis caused by repeated reinfections with Chlamydia trachomatis. Trachoma is a disease of entire communities, with the reservoir of infection residing in children, especially preschool children. The World Health Assembly has targeted the year 2020 for the elimination of blinding trachoma as a public health problem, and mass treatment with antibiotics is part of the multifaceted SAFE strategy recommended for country programs. Tanzania was one of the first countries to be the recipient of azithromycin for use in mass distribution programs and has been the site of a continuous research effort on trachoma control in the Kongwa district, the Kongwa Trachoma Project, since 1986. The authors discuss some events leading up to the use of azithromycin for trachoma, our experiences and lessons learned with use of azithromycin, intervention goals, achieving high coverage and the challenges to achieving elimination by 2020.

AB - Trachoma, the leading infectious cause of blindness, is a chronic conjunctivitis caused by repeated reinfections with Chlamydia trachomatis. Trachoma is a disease of entire communities, with the reservoir of infection residing in children, especially preschool children. The World Health Assembly has targeted the year 2020 for the elimination of blinding trachoma as a public health problem, and mass treatment with antibiotics is part of the multifaceted SAFE strategy recommended for country programs. Tanzania was one of the first countries to be the recipient of azithromycin for use in mass distribution programs and has been the site of a continuous research effort on trachoma control in the Kongwa district, the Kongwa Trachoma Project, since 1986. The authors discuss some events leading up to the use of azithromycin for trachoma, our experiences and lessons learned with use of azithromycin, intervention goals, achieving high coverage and the challenges to achieving elimination by 2020.

KW - azithromycin

KW - ocular Chlamydia trachomatis infection

KW - population study

KW - Tanzania

KW - trachoma

UR - http://www.scopus.com/inward/record.url?scp=84879627134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879627134&partnerID=8YFLogxK

U2 - 10.1586/eop.13.18

DO - 10.1586/eop.13.18

M3 - Article

VL - 8

SP - 245

EP - 253

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

IS - 3

ER -